Loading company…
Riskpilot
← Back to search
Sign in
Get full access
Pharmavizer AB
AB
Active
Org 5568335854
Research and experimental development on natural sciences and engineering · NACE 7210
Est. 2010
0 employees
Watchlist
Share
Overview
Financials
People & ownership
Related companies
Revenue 2024
SEK -1
-100% vs 2023
EBITDA margin
-190400.0%
+115% vs 2023
Equity ratio
69.9%
Financial strength
Net profit 2024
SEK 2K
-96% vs 2023
EBITDA — year on year
SEK millions
0M
-0M
-1M
-1M
-1M
0M
2020
0M
0%
2021
0M
0%
2022
0M
0%
2023
0M
0%
2024
Key figures
Annual report 2024
Revenue
SEK -1
-100%
EBITDA
SEK 2K
+115%
Net profit
SEK 2K
-96%
Total assets
SEK 701K
-7%
Equity
SEK 490K
+0%
Employees
0
—
Company information
Legal name
Pharmavizer AB
Org number
5568335854
Legal form
Aktiebolag
NACE code
7210 · Research and experimental development on natural sciences and engineering
Founded
17 december 2010
Share capital
SEK 50 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen
Company purpose
Konsultverksamhet inom läkemedelsutveckling och hälsovård. Förvaltning och handel med aktier och andra finansiella instrument.
Contact
Address
Phone
+4640268182
Email
per.bengtsson54@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Visit risika.com
Explore
Companies in Research and experimental development on natural sciences and engineering
Companies in Malmö
All Sweden companies
Revenue
SEK millions
0M
0M
1M
1M
1M
0M
2020
1M
2021
0M
2022
0M
2023
0M
2024
EBITDA
SEK millions
0M
0M
1M
1M
1M
0M
2020
0M
2021
0M
2022
0M
2023
0M
2024
Income statement
SEK thousands
Item
2020
2021
2022
2023
2024
Revenue
286
608
131
65
−0
Staff expenses
—
—
−64
−39
30
EBITDA
123
496
−7
−13
2
Depreciation & amort.
−8
−0
—
—
—
EBIT
115
496
−7
−13
2
Net financials
—
—
0
1
1
Profit before tax
115
542
−7
54
3
Tax
−25
−116
−0
−13
−1
Net profit
90
426
−7
41
2
Balance sheet
SEK thousands
Item
2020
2021
2022
2023
2024
Total assets
591
948
910
756
701
Equity
143
480
447
488
490
Long-term debt
0
0
—
—
—
Short-term debt
147
214
209
80
23
Total debt
147
214
209
80
23
Financial ratios
5-year trend
EBITDA margin
190400.0%
This company
15.8%
Market median
+1204963% vs market
2020
2024
Equity ratio
69.9%
This company
38.2%
Market median
+83% vs market
2020
2024
Return on equity
0.4%
This company
18.4%
Market median
-98% vs market
2020
2024
Net profit margin
180000.0%
This company
8.1%
Market median
+2222122% vs market
2020
2024
Asset turnover
-0.00×
This company
1.12×
Market median
-100% vs market
2020
2024
Debt / equity
0.43×
This company
0.62×
Market median
+31% vs market
2020
2024
Annual reports & filings
Annual report 2024
Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
View
PDF
Annual report 2023
Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
View
PDF
Annual report 2022
Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
View
PDF
Annual report 2021
Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
View
PDF
Annual report 2020
Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
View
PDF
Management
Actively employed in the business
No data on file.
Board of directors
Non-executive oversight
Name
Role
Member since
Current (2)
PM
Per Martin Bengtsson
Board of Directors
2022
AM
Axel Martin Petter Bengtsson
Deputy Board Member
2022
Shareholders
As of last annual report
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive.
Learn more
.
Company hierarchy
No registered parent or subsidiaries
Board network connections
Board members of Pharmavizer AB also hold positions in
0
other companies.
Person
Role here
Other companies
Per Martin Bengtsson
Board of Directors
0 companies
Axel Martin Petter Bengtsson
Deputy Board Member
0 companies